These findings provide a basis for developing drugs that can differentially target the α1 and α2 subunits of AMPK to treat diseases such as obesity and osteoporosis that are associated with mutations in specific AMPK subunits. The gene discussed is PRKAA1; the disease is obesity due to melanocortin 4 receptor deficiency.